Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001 | 0.98 | HSD17B10 (0.52) | HSD17B10SLC6A9S1PR1ITGB3ITGA2B | |
| SCHEMBL2916590 | 0.89 | HSD17B10 (0.45) | HSD17B10SLC6A9ITGB3ITGA2BTSHR | |
| Tetraxetan SCHEMBL2017956 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| SCHEMBL321989 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| SCHEMBL3660521 | 0.84 | — | — | |
| SCHEMBL6848102 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| Tetraxetan SCHEMBL2635294 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| Tetraxetan SCHEMBL18018 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| SCHEMBL173508 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA | |
| SCHEMBL6744121 | 0.84 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0755385-B1 | CHELANT COMPOUNDS | AMERSHAM HEALTH AS (NO) | 2004-02-11 | — | — | EP | claimed |
| US-5798089-A | Chelant moieties linked to an aryl moiety by an interrupted alkylene linker | NYCOMED SALUTAR, INC. (US) | 1998-08-25 | — | — | US | claimed |
| EP-0755385-A1 | CHELANT COMPOUNDS | NYCOMED IMAGING AS (NO) | 1997-01-29 | — | — | EP | claimed |
| WO-1995028392-A1 | CHELANT COMPOUNDS | NYCOMED SALUTAR INC. (US) | 1995-10-26 | — | — | WO | claimed |
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6693190-B1 | TETRAAZACYCLODODECANE MACROCYCLE DERIVATIVES INCLUDING METAL COMPLEXES; MAGNETIC RESONANCE IMAGING AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2004-02-17 | — | — | US | disclosed |
| EP-0708761-B1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INT BV (NL) | 2002-08-14 | — | — | EP | disclosed |
| WO-1995031444-A1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | H1-2, H1-0, H1-3 | HSD17B10 4183/4885SLC6A9 3108/4885S1PR1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.